Group 1: Yuanji Food - Yuanji Food Group submitted its prospectus to the Hong Kong Stock Exchange on January 12, 2026, aiming for a main board listing, with Huatai International and GF Securities as joint sponsors [3] - Established in 2017, Yuanji Food has become the largest Chinese and global fast-food enterprise, focusing on handmade dumplings and wontons, with 4,266 stores across China and Southeast Asia as of September 30, 2025 [3] - The gross merchandise value (GMV) for Yuanji Food's stores was 4.772 billion yuan in 2023 and 6.247 billion yuan in 2024, representing a year-on-year growth of 30.9% [3] - Revenue for Yuanji Food was 2.026 billion yuan in 2023 and 2.561 billion yuan in 2024, with a year-on-year growth of 26.4% [4] Group 2: Qian Dama - Qian Dama International Holdings submitted its prospectus to the Hong Kong Stock Exchange on January 12, 2026, with CICC and Agricultural Bank of China International as joint sponsors [5] - Founded in 2014, Qian Dama focuses on providing fresh, high-quality products and a convenient shopping experience, leading the community fresh retail market in South China with a GMV of approximately 9.8 billion yuan in 2024 [5][6] - As of September 30, 2025, Qian Dama operated 2,938 community stores across 14 provinces and municipalities in China [6] - Revenue for Qian Dama was 11.744 billion yuan in 2023 and 11.787 billion yuan in 2024, with a gross margin of 10.2% in 2024 [7] Group 3: Big Pizza - Big Restaurant International Holdings submitted its prospectus to the Hong Kong Stock Exchange on January 16, 2026, with Bank of China International as the sole sponsor [8] - Established in 2002, Big Pizza operates 342 stores across 28 provinces and cities in China, with plans to open approximately 610 to 790 new stores from 2026 to 2028 [8][9] - The GMV for Big Pizza was 1.7 billion yuan in the first three quarters of 2025, ranking first among local pizza restaurants in China [9] - Revenue for Big Pizza was 944 million yuan in 2023 and 1.147 billion yuan in 2024, with a significant increase of 66.6% to 1.389 billion yuan in the first three quarters of 2025 [10] Group 4: Zeling Bio - Chengdu Zeling Biomedical Technology submitted its prospectus to the Hong Kong Stock Exchange on January 13, 2026, with Jefferies and CICC as joint sponsors [12] - Founded in 2019, Zeling Bio focuses on developing differentiated small molecule therapies for unmet medical needs in blood system diseases, tumors, and CNS diseases [12] - As of January 5, 2026, Zeling Bio has established a pipeline of eight proprietary assets, including two core products in Phase III clinical trials [12][13] Group 5: Exegenesis Bio - Exegenesis Bio Inc. submitted its prospectus to the Hong Kong Stock Exchange on January 14, 2026, with CCB International as the sole sponsor [15] - Founded in 2019, Exegenesis Bio specializes in gene therapy and oligonucleotide drugs, with a focus on innovative delivery systems [15][16] - The core candidate product EXG001-307 is a potential best-in-class therapy for spinal muscular atrophy (SMA) type 1, currently in the registration clinical trial phase [16] Group 6: Yuyuantang - Harbin Yuyuantang Traditional Chinese Medicine Clinic Group submitted its prospectus to the Hong Kong Stock Exchange on January 16, 2026, with 招银国际 and 国元国际 as joint sponsors [17] - Established in 2018, Yuyuantang provides a full lifecycle treatment model for traditional Chinese medicine, operating 48 licensed medical institutions in Northern China as of January 6, 2026 [17][18] - Revenue for Yuyuantang was 150 million yuan in 2023 and 215 million yuan in 2024, with a significant increase of 96.6% to 284 million yuan in the first three quarters of 2025 [18] Group 7: Laoxiangji - LXJ International Holdings updated its prospectus for the Hong Kong Stock Exchange, continuing its listing process with CICC and Guotai Junan as joint sponsors [19] - Founded in 2003, Laoxiangji operates 1,658 stores across 61 cities in China, with a market share of 0.9% in the Chinese fast-food industry [19][20] - Revenue for Laoxiangji was 4.528 billion yuan in 2022, 5.651 billion yuan in 2023, and 6.288 billion yuan in 2024, with a 10.9% increase to 4.578 billion yuan in the first eight months of 2025 [20][21] Group 8: Immvira Bioscience - Immvira Bioscience updated its prospectus for the Hong Kong Stock Exchange on January 14, 2026, with Citigroup and CICC as joint sponsors [22] - Immvira is a biotechnology company with a focus on oncolytic immunotherapy candidates and innovative engineered exosome therapeutic products [22] - The core product MVR-T3011 targets a wide range of solid tumors, including bladder cancer and head and neck squamous cell carcinoma [22]

Core Viewpoint - The article provides an overview of recent IPO activities in Hong Kong, the US, and A-shares, highlighting several companies that have submitted their prospectuses for listing on the Hong Kong Stock Exchange. Group 1: Yuanji Food - Yuanji Food Group Co., Ltd. submitted its prospectus to the Hong Kong Stock Exchange on January 12, 2026, aiming for a main board listing, with Huatai International and GF Securities as joint sponsors [3] - Established in 2017, Yuanji Food has become the largest Chinese fast-food enterprise globally and the largest dumpling and wonton company in China, focusing on "handmade, freshly wrapped and cooked" products [3] - As of September 30, 2025, Yuanji Food operated 4,266 stores across China and Southeast Asia, with a GMV of 47.72 billion yuan in 2023 and 62.47 billion yuan in 2024, representing a year-on-year growth of 30.9% [4] Group 2: Qian Dama - Qian Dama International Holdings Limited submitted its prospectus to the Hong Kong Stock Exchange on January 12, 2026, with CICC and Agricultural Bank of China International as joint sponsors [6] - Founded in 2014, Qian Dama focuses on providing fresh, high-quality products and has pioneered the "discount day clearance" sales model, becoming the absolute leader in the community fresh food retail market in South China [6] - As of September 30, 2025, Qian Dama had 2,938 community stores across 14 provinces, with a GMV of 148 billion yuan in 2024 [7] Group 3: Big Pizza - Big Restaurant International Holdings Limited submitted its prospectus to the Hong Kong Stock Exchange on January 16, 2026, with Bank of China International as the sole sponsor [10] - Established in 2002, Big Pizza operates 342 stores across 28 provinces and cities in China, with plans to open approximately 610 to 790 new stores from 2026 to 2028 [10] - In the first three quarters of 2025, Big Pizza achieved a GMV of 17 billion yuan, ranking first among domestic pizza restaurants [10] Group 4: Zeling Bio - Chengdu Zeling Biopharmaceutical Technology Co., Ltd. submitted its prospectus to the Hong Kong Stock Exchange on January 13, 2026, with Jefferies and CICC as joint sponsors [14] - Founded in 2019, Zeling Bio focuses on developing innovative small molecule therapies for unmet medical needs in blood system diseases, tumors, and CNS diseases [14] - As of January 5, 2026, Zeling Bio has established a pipeline of eight proprietary assets, including two core products in Phase 3 clinical trials [14] Group 5: Jia Yin Bio - Exegenesis Bio Inc. submitted its prospectus to the Hong Kong Stock Exchange on January 14, 2026, with Jianyin International as the sole sponsor [18] - Founded in 2019, Jia Yin Bio specializes in gene therapy and oligonucleotide drugs, with a focus on developing a diverse and scalable product pipeline [18] - The core candidate product EXG001-307 is a potential best-in-class therapy for spinal muscular atrophy (SMA) type 1, currently in the registration clinical trial phase [19] Group 6: Yu Yan Tang - Harbin Yu Yan Tang Traditional Chinese Medicine Clinic Group Co., Ltd. submitted its prospectus to the Hong Kong Stock Exchange on January 16, 2026, with 招银国际 and 国元国际 as joint sponsors [21] - Established in 2018, Yu Yan Tang provides a full lifecycle of TCM medical services, operating a network of 48 licensed medical institutions in northern China [21] - The company ranked fifth among private chain TCM service providers in China by total revenue in 2024, with a customer repurchase rate of 81.1% in the first three quarters of 2025 [22] Group 7: Lao Xiang Ji - LXJ International Holdings Limited updated its prospectus to continue the listing process on the Hong Kong Stock Exchange, with CICC and Guotai Junan as joint sponsors [24] - Founded in 2003, Lao Xiang Ji operates 1,658 stores across 61 cities in China, with a market share of 0.9% in the Chinese fast-food industry [24] - The company reported revenues of 45.28 billion yuan in 2022, 56.51 billion yuan in 2023, and 62.88 billion yuan in 2024, with a 10.9% increase in revenue in the first eight months of 2025 [26]

Investment Rating - The report maintains a "Recommended" rating for the new materials industry [1] Core Insights - The new materials sector is positioned as a crucial direction for the chemical industry, currently experiencing rapid growth in downstream demand. With policy support and technological breakthroughs, domestic new materials are expected to accelerate into a long-term growth phase. The report emphasizes that "one generation of materials leads to one generation of industry," highlighting the foundational nature of the new materials industry as the material basis for other sectors [3][4]. Summary by Sections 1. Electronic Information Sector - Focus areas include semiconductor materials, display materials, and 5G materials. Samsung Display has officially launched mass production of the 8.6 generation OLED panels, which will be used in new laptops this year [5][20]. 2. Aerospace Sector - Key materials of interest are PI films, precision ceramics, and carbon fibers. The successful suborbital flight test of the Lihong No. 1 vehicle demonstrates advancements in low-cost and flexible launch capabilities [7]. 3. New Energy Sector - Focus on photovoltaic materials, lithium-ion batteries, proton exchange membranes, and hydrogen storage materials. India is projected to become the second-largest solar market globally by 2026, driven by steady installation growth [9]. 4. Biotechnology Sector - Key areas include synthetic biology and scientific services. A team from Tsinghua University in Shenzhen has developed a 3D-printed "mini heart" that mimics the rhythmic beating of a real heart, with future applications in organ printing anticipated [11]. 5. Energy Conservation and Environmental Protection Sector - Focus on adsorbent resins, membrane materials, and biodegradable plastics. The Ministry of Industry and Information Technology has launched an action plan to promote high-quality development of industrial internet platforms, aiming for over 450 influential platforms by 2028 [13]. 6. Key Companies and Earnings Forecast - The report highlights several companies with their respective stock prices and earnings per share (EPS) forecasts for 2024A, 2025E, and 2026E, along with their price-to-earnings (PE) ratios and investment ratings. Notable companies include: - Ruihua Tai (688323.SH): EPS forecast of 0.26 for 2026E, rated as "Increase" [14] - Guangwei Composite (300699.SZ): EPS forecast of 0.97 for 2026E, rated as "Buy" [14] - Zhongfu Shenying (688295.SH): EPS forecast of 0.23 for 2026E, rated as "Buy" [14] - Wanrun Co., Ltd. (002643.SZ): EPS forecast of 0.53 for 2026E, rated as "Buy" [14] - Dinglong Co., Ltd. (300054.SZ): EPS forecast of 0.96 for 2026E, rated as "Buy" [14]

Summary of Precigen's Presentation at the J.P. Morgan Healthcare Conference Company Overview - **Company**: Precigen - **Industry**: Biotechnology, focusing on cell and gene therapy for rare diseases and oncology - **Location**: Maryland, USA - **Key Product**: Pepcimeus, an FDA-approved drug for recurrent respiratory papillomatosis (RRP) [2][9] Core Points and Arguments Advancements in Technology and Product Development - Precigen utilizes a differentiated adenovirus platform, specifically gorilla adenoviral vectors, which have a payload capacity of 12 to 15 kb, allowing for more genes to be delivered compared to traditional adenoviruses [3][4] - The platform enables repeat dosing without the high titers of neutralizing antibodies that typically inhibit efficacy in other adenoviral vectors, promoting T cell immunity [5][6] - Pepcimeus was developed and received FDA approval in just four years, showcasing the efficiency of Precigen's development process [3][9] Clinical Data and Patient Impact - Pepcimeus is the first FDA-approved therapy for RRP, a condition caused by HPV 6 and 11, leading to benign tumors in the respiratory tract [10][12] - Clinical trials showed that patients who previously underwent multiple surgeries experienced significant reductions in surgical needs after receiving Pepcimeus [15][16] - The drug is administered subcutaneously, similar to a flu vaccine, making it easy for patients to receive [13][14] Market Potential and Commercialization Strategy - The U.S. market for RRP is estimated at 27,000 patients, with potential expansion to 35,000 patients in Europe and 85,000 in China [17][22] - Precigen has secured coverage for Pepcimeus through Medicare, Medicaid, and over 170 million lives across various private health insurances, achieving nearly 80% coverage within a quarter of launch [19][37] - The company has established a patient support hub, which has seen rapid growth in patient enrollment, indicating strong market interest [20][21] Future Plans and Regulatory Strategy - Precigen plans to expand Pepcimeus' indications to pediatric patients and is pursuing regulatory approval in the EU and Japan [23][24] - The company aims to leverage its adenovirus platform for additional indications, including HPV-related cancers, with ongoing Phase 2 trials [24][25] Additional Important Insights - The transition from surgical to medical management of RRP represents a significant shift in treatment paradigms, with the potential to improve patient outcomes and reduce the need for invasive procedures [31][32] - Precigen's leadership team has demonstrated expertise in navigating the complexities of drug development and commercialization, contributing to the company's rapid progress since its inception in 2020 [25][26] - The company is focused on establishing partnerships for international expansion while maintaining a primary focus on the U.S. market [39][40]

Financial Data and Key Metrics Changes - The meeting discussed the approval of the Continuance Resolution and Domestication Resolution, which were passed by a majority of not less than 2/3 of the votes cast [19] - The 2026 Incentive Award Plan also received majority approval from the votes cast [19] Business Line Data and Key Metrics Changes - No specific business line data or key metrics were provided during the meeting Market Data and Key Metrics Changes - No specific market data or key metrics were discussed during the meeting Company Strategy and Development Direction and Industry Competition - The company is transitioning from Alberta to British Columbia and then to Nevada, indicating a strategic move to potentially enhance operational flexibility and regulatory advantages [9][12] Management's Comments on Operating Environment and Future Outlook - Management did not provide specific comments on the operating environment or future outlook during this meeting Other Important Information - The meeting was conducted virtually, ensuring shareholder rights were protected and participation was facilitated [3][4] - The voting results will be filed on SEDAR and made available on the company's website [20] Q&A Session All Questions and Answers - No specific questions were raised during the meeting regarding the motions presented [12][15][18][22]

Financial Data and Key Metrics Changes - The meeting discussed the approval of the Continuance Resolution and Domestication Resolution, which were passed by a majority of not less than two-thirds of the votes cast [20] - The 2026 Incentive Award Plan was also approved by a majority of the votes cast [20] Business Line Data and Key Metrics Changes - No specific business line data or key metrics were provided during the meeting Market Data and Key Metrics Changes - No specific market data or key metrics were discussed during the meeting Company Strategy and Development Direction - The company is transitioning from Alberta to British Columbia and then domesticated to Nevada, indicating a strategic move to align with favorable business regulations [9][12] Management Comments on Operating Environment and Future Outlook - Management did not provide specific comments on the operating environment or future outlook during this meeting Other Important Information - The meeting was conducted virtually, ensuring shareholder rights were protected and participation was similar to past in-person meetings [3][4] - The voting process was outlined, allowing registered shareholders to vote on resolutions [5][6] Q&A Session Summary - No specific questions were raised during the meeting regarding the motions presented [12][15][18][23]

Core Viewpoint - Immvira Bioscience is advancing its IPO process with a pre-IPO valuation of $485 million, focusing on innovative cancer therapies and leveraging its unique capabilities in CMC and production [1][9]. Company Overview - Immvira Bioscience is the only biotechnology company globally with mature CMC and production capabilities, offering a pipeline that includes oncolytic immunotherapy candidates for solid tumors and innovative engineered exosome therapeutic products [3]. Product Pipeline - The core product, MVR-T3011, is a novel oncolytic immunotherapy based on HSV-1, designed to target a wide range of solid tumors, including bladder cancer and head and neck squamous cell carcinoma [5]. - MVR-T3011 is undergoing a structured development roadmap, with a phased strategy in bladder cancer, including a key Phase II clinical trial for high-risk NMIBC, which is set to complete its first patient dosing in June 2025 [5][6]. - The company has reported promising efficacy and safety data for MVR-T3011 in treating BCG-unresponsive NMIBC, with a 20% objective response rate and a 65% disease control rate observed in prior studies [6]. Regulatory and Development Strategy - The company benefits from a unified "umbrella IND" regulatory framework, allowing multiple clinical evaluations under a single protocol, which enhances development efficiency [7]. - Immvira has established a collaboration with Shanghai Pharmaceuticals for the clinical development and commercialization of MVR-T3011 in Greater China, receiving an upfront payment of 20 million yuan and potential milestone payments up to 1.1 billion yuan [8]. Innovation Platform - The OVPENS platform is central to Immvira's innovative product development, integrating oncolytic immunotherapy and engineered exosome development, covering the entire process from target validation to IND application and GMP-compliant production [8]. - The platform's expansion has also advanced the pipeline of engineered exosome products, which include commercially viable aesthetic products and therapeutic candidates undergoing traditional clinical regulatory pathways [9]. Investment and Valuation - Since its establishment, Immvira has attracted investments from various institutions, with a post-Series C valuation of $485 million [9].

Dyne Therapeutics Conference Call Summary Company Overview - **Company**: Dyne Therapeutics (NasdaqGS:DYN) - **Industry**: Biotechnology, focusing on neuromuscular diseases Key Points and Arguments Transformative Assets - Dyne Therapeutics has two late-stage assets targeting Duchenne Muscular Dystrophy (DMD) and Myotonic Dystrophy Type 1 (DM1), both of which address significant unmet medical needs [2][3] - The company plans to submit its first Biologics License Application (BLA) in 2026 and launch its first commercial product in Q1 2027, with another product following a year later [2][3] Financial Position - Dyne has a strong cash position exceeding $1 billion, allowing for the development and commercialization of its assets [2] Delivery Platform - The company’s FORCE platform utilizes an antibody fragment to target the transferrin receptor, facilitating the delivery of genetic medicines to muscle and central nervous system (CNS) tissues [3][4] - This platform has shown promising results in non-human primate studies, demonstrating effective delivery of oligonucleotides to critical tissues [5] Clinical Validation - In 2025, Dyne validated its platform in humans, with the first medicine, zurastadersen, showing significant functional improvements in DMD patients [6][12] - The DELIVER trial demonstrated a seven-fold increase in dystrophin levels, a key surrogate marker for DMD, with a p-value of 0.0001, indicating strong statistical significance [11] Functional Improvements - Patients treated with zurastadersen showed improvements in various functional measures, including time to rise and walking speed, compared to placebo [12][14] - The treatment also stabilized lung capacity, which is critical for non-ambulatory patients [14] Market Opportunity - Dyne aims to create a franchise by developing additional exon-skipping therapies for DMD, potentially tripling the market size for the condition [9][18] - The company is also preparing to enter the DM1 market, which is larger and currently lacks approved therapies [20] Regulatory Strategy - Dyne has received breakthrough designation from the FDA for both DMD and DM1, facilitating ongoing dialogue regarding accelerated approval pathways [33][35] - The company is on track to submit data for accelerated approval in Q2 2026 [11][35] Manufacturing and Commercialization - Dyne has established a global supply chain and manufacturing capabilities to support its commercial launch [31] - The company anticipates competitive gross margins similar to other rare disease antibody companies, leveraging efficiencies across its pipeline [32] Future Plans - Dyne plans to initiate a confirmatory Phase 3 study for DMD in Q2 2026, focusing on clinically meaningful endpoints [37][49] - The company is also prioritizing the development of FSHD as the next program in the clinic, alongside ongoing efforts for other DMD exons [39] Additional Important Information - The company has a favorable safety profile from its trials, with most treatment-emergent adverse events being mild or moderate [15][25] - Dyne is actively working to address capacity issues in its clinical trials by increasing the number of enrollment sites [40][41] This summary encapsulates the key points from Dyne Therapeutics' conference call, highlighting the company's strategic direction, clinical advancements, and market potential in the biotechnology sector focused on neuromuscular diseases.

Summary of Annexon Conference Call Company Overview - **Company**: Annexon - **Industry**: Biotechnology, specifically focusing on immunotherapy for neuroinflammatory diseases - **Mission**: Deliver game-changing immunotherapy for patients suffering from devastating neuroinflammatory diseases [2][3] Key Programs and Market Opportunities ANX007 for Geographic Atrophy (GA) - **Market Opportunity**: Addressing a market potential of over $10 billion annually, with the ability to treat more than 10 million patients [3][4] - **Phase 3 Data**: Expected release in the second half of 2026, with a focus on vision preservation in patients with GA [4][22] - **Patient Demographics**: Average age of patients in studies is 79 years, with significant vision loss impacting independence [11] - **Efficacy**: Demonstrated protection of 50%-60% of photoreceptor cells, leading to a 73% reduction in the risk of vision loss over 12 months [15][18][19] - **Safety Profile**: Low incidence of adverse events compared to other therapies, with no significant conversion to wet AMD [25] ANX005 for Guillain-Barré Syndrome (GBS) - **Market Opportunity**: Affects 150,000 people worldwide, with a healthcare cost exceeding $7 billion annually in the U.S. [27][28] - **Efficacy**: 90% of treated patients showed improvement by week one, with significant reductions in inflammatory biomarkers [30][31] - **Patient Outcomes**: Patients returned to walking 31 days sooner and were off ventilators 28 days earlier compared to placebo [32] - **Regulatory Status**: Filed for European approval, with plans to submit to the FDA later in 2026 [34] ANX1502 for Autoimmune Conditions - **Development Status**: First oral small molecule candidate targeting autoimmune conditions, with proof of concept data expected in 2026 [5][35] - **Challenges**: Initial formulation issues related to emesis and food effects have been addressed with enteric-coated formulations [46][48] Competitive Advantage - **Scientific Approach**: Focus on targeting C1q in the classical pathway, differentiating from first-generation therapies targeting downstream pathways [6][24] - **Experienced Leadership**: The team has over 100 years of combined biotech experience, enhancing the company's ability to navigate challenges [9] Regulatory and Commercial Strategy - **Regulatory Designations**: Prime designation in the EU and fast track designation in the U.S. for ANX007 [22][40] - **Market Preparation**: Actively preparing for market entry with effective medical education and pre-commercial activities [5] Conclusion - **Transformational Year**: 2026 is positioned as a pivotal year for Annexon, with significant milestones expected in both GA and GBS programs [34] - **Investment Opportunity**: The company presents a unique value proposition for investors, particularly with its late-stage programs and differentiated therapeutic approaches [9][23]

Core Insights - UBS identifies five long-term investment themes that currently present the most attractive opportunities: Digital Consumers, Empowering Technologies, Diversity and Equality, Family Businesses, and Exploring New Frontiers [1] Group 1: Digital Consumers - The younger generation, as digital natives, has different consumption patterns compared to their parents, influencing their behaviors [2] - The theme ranks first among UBS's long-term investment themes due to high quality metrics, involving companies with strong balance sheets and high returns on invested capital [2] - The theme benefits from the robust performance of the technology sector driven by AI trends, although it is noted that valuations are relatively high [2] Group 2: Empowering Technologies - UBS identifies five key empowering technologies: AI, AR/VR, Big Data, Blockchain, and other disruptive technologies, which are expected to transform various industries [3] - The market size for these technologies is projected to grow from $287 billion in 2022 to $3.2 trillion by 2030, with AI expected to account for 90% of this growth [3] - The theme maintains a strong position in UBS's long-term investment themes due to its high momentum score, particularly favoring the information technology sector [3] Group 3: Diversity and Equality - UBS anticipates improvements in global regulatory frameworks for information disclosure and fairness, which could enhance GDP over the next decade [4] - Companies that promote diversity and equality throughout their value chains are expected to perform well in the long term [4] - The theme remains a top investment choice due to favorable valuations and quality scores, with a balanced distribution across various industries [5] Group 4: Family Businesses - Family businesses account for two-thirds of global enterprises and contribute over 70% of global GDP, providing significant employment [6] - UBS estimates that family businesses represent 20-30% of global stock market value, benefiting from conservative financial management and capital discipline [6] - The theme is expected to leverage economic recovery, particularly in Europe, where industrial activity is projected to improve by 2026 [7] Group 5: Exploring New Frontiers - Emerging and frontier economies are seen as key drivers of global GDP growth over the next decade, with demographic factors playing a crucial role [8] - UBS believes that these markets offer attractive returns and diversification opportunities, despite being inherently riskier [8] - The increasing U.S. fiscal deficit and a weakening dollar are making emerging markets more appealing for investors seeking to diversify away from U.S. assets [8] Group 6: Short-term Headwinds for Gene Therapy and Digital Health - Gene therapy and digital health themes currently rank low in UBS's quantitative model, facing short-term headwinds and lower valuation attractiveness [9] - The biotechnology sector, particularly small-cap firms, is experiencing significant capital acquisition challenges, impacting their operational environment [10] - Despite the potential of AI applications in healthcare, the current landscape lacks scalable, data-driven growth drivers, leading to a cautious outlook for these themes [11]